Efficacy and safety of the compound Chinese medicine SaiLuoTong in vascular dementia: A randomized clinical trial-Reference-Cited by-同舟云学术

Efficacy and safety of the compound Chinese medicine SaiLuoTong in vascular dementia: A randomized clinical trial

Published:2018-01 Issue:1 Volume:4 Page:108-117
ISSN:2352-8737
Container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions
language:en
Short-container-title:Alzheimer's & Dementia: Translational Research & Clinical Interventions

Author:

Jia Jianping¹²³⁴⁵,Wei Cuibai¹,Chen Shuoqi¹,Li Fangyu¹,Tang Yi¹,Qin Wei¹,Shi Lu¹,Gong Min¹,Xu Hui¹,Li Fang⁶,He Jia⁷,Song Haiqing¹,Yang Shanshan⁸,Zhou Aihong¹,Wang Fen¹,Zuo Xiumei¹,Chu Changbiao¹,Liang Junhua¹,Jia Longfei⁹,Gauthier Serge¹⁰

Affiliation:

1. Innovation Center for Neurological DisordersDepartment of NeurologyXuan Wu Hospital, Capital Medical UniversityBeijingChina

2. Beijing Key Laboratory of Geriatric Cognitive DisordersBeijingChina

3. Center of Alzheimer's Disease, Beijing Institute for Brain DisordersBeijingChina

4. Key Laboratory of Neurodegenerative Diseases, Ministry of EducationBeijingChina

5. National Clinical Research Center for Geriatric DisordersBeijingChina

6. Department of GerontologyFuxing Hospital, Capital Medical UniversityBeijingChina

7. Department of Health StatisticsSecond Military Medical UniversityShanghaiChina

8. Department of NeurologyDaqing Oilfield General HospitalChina

9. Department of NeurologyHenry Ford HospitalDetroitMIUSA

10. Centre for Studies in AgingMcGill UniversityMontrealQCCanada

Funder

National Key Scientific Instrument and Equipment Development Projects of China

Publisher

Wiley

Subject

Psychiatry and Mental health,Neurology (clinical)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1016/j.trci.2018.02.004

Reference27 articles.

1. Vascular dementia

2. The prevalence of dementia in urban and rural areas of China

3. Prevalence, Incidence, and Mortality of Stroke in China

4. Division of Neuropharmacologic Drug Products US Food and Drug Administration (FDA).Issues Paper on Vascular Dementia Peripheral and Central Nervous System Advisory Committee meeting2001 Available at:http://www.fda.gov/ohrms/dockets/ac/01/briefing/3724b2_01_VasDementia.pdf. Accessed July 17 2007.

5. Committee for Proprietary Medicinal Products of the European Agency for the Evaluation of Medicinal Products Human Medicines Evaluation Unit.Note for Guidance on Medicinal Products in the Treatment of Alzheimer's Disease.1997 Available at:http://www.ema.europa.eu/ema/index.jsp?curl=pages/home/Home_Page.jsp&mid=. Accessed July 17 2007.

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A review of SaiLuoTong (MLC-SLT) development in vascular cognitive impairment and dementia;Frontiers in Pharmacology;2024-05-01

2. Current and Future Treatments of Vascular Cognitive Impairment;Stroke;2024-04

3. Vascular dementia: From pathobiology to emerging perspectives;Ageing Research Reviews;2024-04

4. Vascular endothelial growth factor is an effective biomarker for vascular dementia, not for Alzheimer's disease: A meta‐analysis;Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring;2024-04

5. Efficacy of Sailuotong ((sic)(sic)(sic)) on neurovascular unit in amyloid precursor protein/presenilin-1 transgenic mice with Alzheimer's disease;J TRADIT CHIN MED;2024